Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

Ketamine has a long and varied past as a pharmaceutical. It was developed in 1962, tested on subjects in 1964 and approved as an anesthetic in 1970 in the United States. Ketamine was used in the ...

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an inadequate response to at least two oral antidepressants, maker Johnson ...

Esketamine has not yet been FDA-approved for depression treatment. But some experts suggest that, if approved, esketamine administration should follow the path of methadone .

Esketamine, a rapid-onset antidepressant, offers potential advantages for treatment-resistant depression, but its effect on women with perinatal depression is unknown.

Budapest, Hungary — A single dose of intravenous esketamine during delivery or caesarean section appears to reduce the risk for postpartum depression (PPD) by more than 50% in the first 6 weeks ...

Esketamine administered intravenously during elective cesarean delivery may significantly reduce depressive symptoms in the early postpartum period, according to study results published in JAMA ...

Mental health is not just depression, schizophrenia, a mood disorder, anxiety; it has all of the things. We are trying to ...

In March 2019, the VA announced that healthcare providers will now be able to offer the newly approved Esketamine nasal spray, marketed as Spravato, for treatment-resistant depression.. Retired U ...

A single low dose injection of esketamine given immediately after childbirth reduces major depressive episodes in individuals with depressive symptoms during pregnancy (prenatal depression), finds ...

New hope for treatment-resistant depression. Understanding what emotional intelligence looks like and the steps needed to improve it could light a path to a more emotionally adept world.